Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8452W HIGH $2.46
Volume
102.31 K
Value Traded
54.84 K
Short % Float
1.68%
-9.52%Week
-21.49%1 Month
-37.09%3 Month
-45.71%6 Month
-94.55%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
15.84 M
EPS (TTM)
-0.52
P/E Ratio
-
Ent. Value
4.51 M
Total Shares
16.66 M
Float Shares
13.50 M
Insiders
19.03%
Institutions
10.74%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MRKR Catalyst Timeline
Dated clinical, regulatory and corporate events for Marker Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Marker Therapeutics, Inc.
279Total events
3Upcoming
59Tier-1 (high impact)
2010 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Manufacturing MilestoneCMC / Inspection
Cellipont Bioservices and Kincell Bio combine to form Kincellis Advanced Therapies
◆Topline ReadoutMT-601Clinical Data
Data update from APOLLO study in DLBCL expected in Q2 2026
relapsed Diffuse Large B Cell Lymphoma (DLBCL)source ↗
◆Oral PresentationPresentation
CEO Dr. Juan Vera to present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
▲Oral PresentationPresentation
Baylor TACTOPS study featured on Good Morning America
pancreatic cancersource ↗
▲Full ResultsClinical Data
Publication of Phase 1/2 results of Multi-Antigen Targeted T cells in pancreatic cancer in Nature Medicine
pancreatic cancersource ↗
▲PublicationPresentation
Nature Medicine publication on MAR-T cells in pancreatic cancer
pancreatic cancersource ↗
◆Trial InitiationTrial
Clinical initiation of pancreatic cancer program with MAR-T cells
pancreatic cancersource ↗
◆Poster PresentationMT-601Presentation
MT-601 Demonstrates Favorable Safety and Durable Responses in r/r NHL poster at ASH
relapsed or refractory Non-Hodgkin lymphomasource ↗
◆Poster PresentationMT-601Presentation
Safety and Efficacy of MT-601 in r/r Hodgkin Lymphoma poster at ASH
relapsed or refractory Hodgkin lymphomasource ↗
▲Topline ReadoutMT-601Clinical Data
APOLLO study showed 66% ORR, 50% CR in NHL patients
relapsed/refractory B-cell lymphoma (Non-Hodgkin lymphoma)source ↗
▲Enrollment MilestoneMT-601Trial
Advanced to dose expansion phase at highest dose level (400x10^6 cells) in DLBCL patients
Diffuse Large B Cell Lymphoma (DLBCL) relapsed after anti-CD19 CAR-T or ineligiblesource ↗
▲First Patient DosedMT-401-OTSTrial
First patient treated with MT-401-OTS in Phase 1 RAPID study
acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)source ↗
◆Oral PresentationPresentation
Fireside chat at H.C. Wainwright 27th Annual Global Investment Conference
▲Topline ReadoutMT-601Clinical Data
Favorable safety and 66% ORR (50% CR) in 12 NHL patients from APOLLO dose-escalation
Non-Hodgkin Lymphoma (NHL)source ↗
▲Safety Data UpdateMT-601Clinical Data
Favorable safety profile: no DLTs, no ICANS, 2 Grade 1 CRS
relapsed B cell lymphomasource ↗
●Oral PresentationMT-601Presentation
Live webcast to discuss APOLLO results
relapsed B cell lymphomasource ↗
◆Oral PresentationPresentation
Fireside chat at Canaccord Genuity 45th Annual Growth Conference
▲Full ResultsMT-601Clinical Data
Phase 1 APOLLO data update: 66% ORR, 50% CR in relapsed NHL
relapsed non-Hodgkin lymphomasource ↗
▲First Patient DosedTrial
First patient treated in Off-the-Shelf RAPID study
Acute Myeloid Leukemia or Myelodysplastic Syndromesource ↗
▲Partnership / LicenseMT-601Corporate
Manufacturing collaboration established with Cellipont Bioservices
▲Partnership / LicenseMT-601Corporate
Collaboration with Cellipont Bioservices for cGMP manufacturing of MT-601
lymphomasource ↗
▲Dose Finding UpdateMT-601Trial
SRC cleared maximum dose 400x10^6 cells for dose expansion
relapsed B cell lymphomasource ↗
▲Enrollment MilestoneMT-601Trial
24 patients enrolled in dose escalation
relapsed B cell lymphomasource ↗
◆Oral PresentationPresentation
CEO Dr. Juan Vera to participate in virtual webcast panel on CAR-T cell therapies
▲Enrollment UpdateMT-601Trial
Marked increase in patient enrollment in first five months of 2025
lymphomasource ↗
◆Oral PresentationPresentation
CEO panel participation at Canaccord Genuity Horizons in Oncology Conference
◆Oral PresentationMT-601Presentation
Webinar to share additional insights on APOLLO study data
lymphomasource ↗
●Runway Guidance UpdateCorporate
Cash runway guidance: existing cash funds into Q1 2026; additional grants could extend beyond
◆Topline ReadoutMT-601Clinical Data
Clinical data readout from Phase 1 APOLLO study expected later this year
lymphomasource ↗
◆Oral PresentationMT-601Presentation
Plan to present expanded clinical data set later this year
lymphomasource ↗
◆Trial InitiationMT-601Trial
Anticipated clinical program initiation for MT-601 in pancreatic cancer in 2025
metastatic pancreatic cancersource ↗
▲Partnership / LicenseCorporate
Collaboration with Cellipont Bioservices to strengthen manufacturing capabilities
▲Topline ReadoutMT-601Clinical Data
Preliminary data from Phase 1 APOLLO study showed 78% ORR and durable CRs in 9 patients
refractory lymphomas (post anti-CD19 CAR-T)source ↗
▲Other Regulator MilestoneMT-601Ex-US Regulatory
USAN and INN approval of nonproprietary name 'neldaleucel' for MT-601
▼Equity OfferingCorporate
Strategic private placement financing to support clinical advancements
▲Topline ReadoutMT-601Clinical Data
Previously reported objective responses in 7 of 9 participants (78%) with 4 complete responses (44.4%) at 4 weeks
lymphomasource ↗
▲Full ResultsMT-601Clinical Data
Phase 1 APOLLO study results: 78% ORR, 44.4% CR at first assessment
relapsed lymphomasource ↗
●Enrollment UpdateMT-601Trial
10 patients treated, data available for 9; up to 30 planned for dose escalation
relapsed lymphomasource ↗
▲Safety Data UpdateMT-601Clinical Data
MT-601 well tolerated; no ICANS, one Grade 1 CRS, no DLTs
relapsed lymphomasource ↗
▲Other Regulator MilestoneEx-US Regulatory
Marker Therapeutics awarded $9.5 million CPRIT grant for MT-601 in pancreatic cancer
◆Topline ReadoutMT-601Clinical Data
Expect to report preliminary safety and efficacy data from APOLLO study by end of 2024
lymphomasource ↗
◆Timing GuidanceMT-601Presentation
Data availability expected toward latter half of 2024 for MT-601 and MT-401
non-Hodgkin's lymphomasource ↗
◆Timing GuidanceMT-401Presentation
Data availability expected toward latter half of 2024 for MT-401
acute myeloid leukemia (AML) post-transplantsource ↗
Past FDA Catalysts and PDUFA Decisions
How MRKR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | MAR-T cell therapy | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 84%
Micro Cap(rank 553 of 658)
Percentile Rank
Marker Therapeutics, Inc. faces pipeline headwinds (25/100), with $99M risk-adjusted pipeline value, led by MT-601 in Non-Hodgkin Lymphoma, Adult (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT-601 Small moleculeNCT06549751 | Pancreas Cancer | Phase 1 | NOT YET_RECRUITING | 38 | Sep 16, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every MRKR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| MT-601 | relapsed non-Hodgkin lymphoma | Phase 1 | 2026-03-18 | objective response rate: 66%; complete responses: 50%Read More | Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, includiRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ELMS STEVEDirector | Buy | 11,085 325,370 held | $3.20 | 12/23/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in MRKR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| NEA Management Company, LLC | 0.2 % (100 %) | 2.39 M | 1.63 M |
MRKR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MRKR ranks across every disease it competes in
Competitive Position is a premium feature
See how MRKR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMRKR News
MRKRMarker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
Marker Therapeutics has announced enhanced manufacturing support for its lead program MT-601 following the formation of Kincellis Advanced Therapies, a new CDMO created by merging Cellipont Bioservices and Kincell Bio. This partnership aims to bolster the manufacturing foundation as MT-601 progresses into later-stage clinical trials. The APOLLO study is currently evaluating MT-601's efficacy in patients with relapsed lymphoma.
Read more →MRKRMarker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Marker Therapeutics, Inc. reported their 2025 corporate and financial results, highlighting encouraging clinical activity in their Phase 1 APOLLO study where a 66% objective response rate was achieved in relapsed non-Hodgkin lymphoma. The company also announced promising research in pancreatic cancer using their multi-antigen recognizing T cell therapy. They noted an increase in net loss compared to the previous year and emphasized the importance of upcoming data updates and the initiation of new clinical programs over the next 12 to 18 months.
Read more →MRKRMarker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Marker Therapeutics, Inc. will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. CEO Dr. Juan Vera will lead the presentation and participate in one-on-one meetings with investors. The company focuses on developing T cell-based immunotherapies for various cancers and has demonstrated promising results in clinical trials.
Read more →MRKR▼ -11%on this news· ran to -23% by day 3
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
Marker Therapeutics announced that Baylor College of Medicine's pancreatic cancer study utilizing MAR-T cell technology was featured on Good Morning America. The study, published in Nature Medicine, showed promising results in treating pancreatic ductal adenocarcinoma. Marker plans to build on these results in an upcoming study, aiming to improve patient outcomes further.
Read more →MRKR▲ +16.2%on this news· ran to +34% by day 3
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
Baylor College of Medicine's clinical study shows promising results for Multi-Antigen Targeted T cells in pancreatic cancer, achieving an 84.6% disease control rate. The study indicates a favorable safety profile and a median overall survival of 14.1 months. Marker Therapeutics plans to enhance this therapy further and initiate a pancreatic cancer program in 2026.
Read more →MRKRMarker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Marker Therapeutics, Inc. reported its financial results for the third quarter of 2025, highlighting promising outcomes from the ongoing APOLLO study of MT-601 for relapsed B-cell lymphoma. The study showed a 66% objective response rate and a notable 50% complete response rate in heavily pre-treated patients. Additionally, the company announced a strategic collaboration with Cellipont Bioservices to enhance production capabilities. Financially, Marker Therapeutics raised approximately $10 million, extending its cash runway into 2026, despite posting a net loss of $2.0 million for the quarter.
Read more →MRKRMarker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
Marker Therapeutics has appointed Kathryn Penkus Corzo to its Board of Directors, effective November 1, 2025. With over 30 years of experience in biopharma, Ms. Corzo's expertise will support the company's clinical and corporate objectives, particularly in advancing the APOLLO program for CAR-relapsed DLBCL. The MAR-T cell platform aims to enhance treatment options for patients.
Read more →MRKRMarker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
Marker Therapeutics announced that data from the Phase 1 APOLLO study of MT-601 will be presented at the 67th ASH Annual Meeting. The study showed encouraging efficacy and a strong safety profile, with high objective response rates in patients with relapsed Non-Hodgkin and Hodgkin lymphoma. The company is advancing to the dose expansion phase for further evaluation.
Read more →MRKR▲ +13.1%on this news
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Marker Therapeutics has successfully treated the first patient in its Off-the-Shelf (OTS) program as part of the Phase 1 RAPID study. The initial dose of the MAR T cell product was well tolerated, showing no adverse events. The program aims to expedite treatment for patients with acute myeloid leukemia and myelodysplastic syndromes, leveraging commercially available leukapheresis material for faster manufacturing.
Read more →MRKRMarker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Marker Therapeutics, Inc. will have its CEO, Dr. Juan Vera, participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The event will include discussions on the company's Multi-Antigen Recognizing T cell platform and recent updates on the Phase 1 APOLLO study. Investors can register for the event online.
Read more →MRKR▼ -20.6%on this newsshared move
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
Marker Therapeutics has reported encouraging results from its Phase 1 APOLLO study of MT-601 in patients with relapsed B cell lymphoma. The study demonstrated a 66% objective response rate and a 50% complete response rate among Non-Hodgkin Lymphoma patients. No dose limiting toxicities were observed, and the safety profile was favorable. The trial will proceed to a dose expansion phase to further evaluate MT-601's efficacy.
Read more →MRKRMarker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Marker Therapeutics, Inc. will have its CEO, Dr. Juan Vera, participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference from August 12-14, 2025. The event will focus on the company's Multi-Antigen Recognizing T cell platform and its clinical developments. Investors can register to view the event online.
Read more →MRKRMarker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
Marker Therapeutics has partnered with Cellipont Bioservices to enhance the cGMP manufacturing of MT-601, a T cell therapy for lymphoma patients. This collaboration aims to support the ongoing Phase 1 APOLLO study, which has shown promising results with a significant response rate. The partnership is expected to facilitate future pivotal trials and commercial readiness for MT-601.
Read more →MRKRMarker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
Marker Therapeutics reported that lymphodepletion enhances the expansion and persistence of MAR-T cells in lymphoma patients. The Phase 1 APOLLO study shows promising results, with 78% of patients achieving objective responses. The company anticipates a significant increase in clinical data as patient enrollment accelerates. A clinical data readout is expected later this year.
Read more →MRKRMarker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
Marker Therapeutics, Inc. will feature its MAR-T cell therapy platform during a live webcast on May 28, 2025. CEO Dr. Juan Vera will discuss the advantages of this non-engineered multi-antigen approach compared to traditional CAR-T therapies. The event will include a roundtable with prominent experts in the cancer treatment field, aiming to address the effectiveness of CD19 CAR-T cells since their FDA approval.
Read more →MRKR▼ -7.3%on this news· ran to -19% by day 3
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
Marker Therapeutics, Inc. announced that CEO Dr. Juan Vera will participate in a panel at Canaccord Genuity's Horizons in Oncology Virtual Conference. The discussion will focus on innovations in T cell-based immunotherapies, particularly CAR-T and novel approaches in treating solid tumors. The company's MAR-T cell therapy platform aims to target multiple tumor-associated antigens, demonstrating promising results in clinical trials.
Read more →MRKRMarker Therapeutics Reports Year-End 2024 Corporate and Financial Results
Marker Therapeutics has reported its year-end 2024 corporate and financial results, highlighting the promising safety and efficacy of its lead therapy, MT-601, in treating refractory lymphomas. The therapy showed a 78% objective response rate in a preliminary Phase 1 study. Additionally, the company secured over $13 million in non-dilutive funding to further support its clinical programs. However, Marker also reported a net loss of $10.7 million for the fiscal year, up from $8.2 million in 2023.
Read more →MRKR▼ -7.4%on this news
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demon
Marker Therapeutics provided an update on the Phase 1 APOLLO study for MT-601, a T cell therapy for relapsed lymphoma patients. The study reported a significant objective response rate of 78%, with 44.4% of patients achieving a complete response. MT-601 was well tolerated among participants, with no severe side effects noted. This promising data comes as an important option for patients who have had limited treatment alternatives after anti-CD19 CAR-T therapies.
Read more →MRKR▲ +17.7%on this newsshared move
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer Houston, TX
Marker Therapeutics has secured a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to advance its clinical investigation of MT-601 in patients with metastatic pancreatic cancer. The grant will specifically support the Phase 1 PANACEA study, which aims to evaluate the safety and tolerability of the treatment. MT-601 is designed to target multiple tumor-associated antigens, and prior studies show promising safety and efficacy results. The funding adds to the over $30 million in non-dilutive financing the company has received from various governmental sources since its inception.
Read more →MRKRMarker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates Marker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical inve
Marker Therapeutics, Inc. reported its financial results for Q3 2024, highlighting progress in its clinical programs. The company received two $2 million grants from the NIH to aid in the development of MT-601 for lymphoma and pancreatic cancer. The ongoing Phase 1 APOLLO trial is showing encouraging results, and preliminary data is expected by the end of 2024. Despite a reduction in its net loss compared to the prior year, Marker faces increasing operational costs and a notable decrease in cash reserves.
Read more →About Marker Therapeutics, Inc.
Headquarters2450 HOLCOMBE BLVD, HOUSTON, TX, 77021
BIOPHARMAWATCH ELITE PLUS
Trade the next MRKR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime